熱門資訊> 正文
INDVIO宣布2500万美元公开募股定价
2025-07-03 19:57
- 伊諾維奧製藥(INO) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- INOVIO Pharmaceuticals (NASDAQ:INO) on Thursday priced an underwritten public offering of 14.29 million shares of its common stock, along with accompanying Series A and Series B warrants to purchase up to an additional 28.57 million shares. Each share of common stock is being sold together with one Series A warrant and one Series B warrant at a combined public offering price of $1.75. Both warrants carry an exercise price of $1.75 per share. In lieu of shares, investors may also opt to receive pre-funded warrants.
- The offering is expected to close on or about July 7, 2025, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the offering are expected to be around $25 million.
- INO -23.36% premarket to $1.64.
- Source: Press Release
More on Inovio Pharmaceuticals
- Inovio Pharmaceuticals announces proposed public offering of common stock and warrants
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
- Seeking Alpha’s Quant Rating on Inovio Pharmaceuticals
推薦文章
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
